Epigenetics Market to expand by USD 1.14 Bn,at a CAGR of 14.06% through 2023 and 2027
According to Technavio's market assesment, the size of the epigenetics market is expected to grow by 1.14 billion, at a compound annual growth rate of 14.06% through 2022 and 2027,
One of the main factors propelling the market expansion is the increasing use of epigenetics in non-oncology disorders. Because of its connections to a variety of environmental factors, epigenetics—which involves heritable changes in gene expression that are unrelated to DNA alterations—is becoming more and more important in the study of non-oncology disorders.
Snapshot of the Epigenetics Market
As a result of this understanding, epigenetic-based treatments that target enzymes like DNA methyltransferases and histone deacetylases (HDACs) have been developed (DNMTs). HDAC inhibitors have been licenced for use in non-oncology disorders already, and interest in using them for other conditions is growing. DNMT inhibitors are also being investigated for possible medical use.In the upcoming years, it is anticipated that these advancements will spur market expansion.
When it comes to the market palyers CellCentric Ltd., Enzo Biochem Inc., EpiGentek Group Inc., F. Hoffmann La Roche Ltd., Hologic Inc., Illumina Inc., Merck KGaA, New England Biolabs Inc., Pacific Biosciences of California Inc., Perkin Elmer Inc., Promega Corp., QIAGEN NV, Thermo Fisher Scientific Inc., and Zymo Research Corp are some of the most prominent names worth mentioning that are constantly striving with their R & D and market development simultaneously
Download our best-selling sample report for highlights on the market size, growth momentum, regional growth opportunities,market players analysis, and other factors influencing the market growth.
The report provides insights into the following FAQs:
